Acasti Pharma Inc.
ACST
Category
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -2.88 | 0.01% |
| 2025 | -2.88 | 65.40% |
| 2024 | -1.74 | 230.12% |
| 2023 | -0.53 | -71.97% |
| 2022 | -1.88 | 397.94% |
| 2021 | -0.38 | 81.82% |
| 2020 | -0.21 | 80.16% |
| 2019 | -0.12 | 35.92% |
| 2018 | -0.08 | 0.00% |
| 2017 | 0.00 | -100.00% |
| 2016 | -0.19 | -69.14% |
| 2015 | -0.63 | 1,021.03% |
| 2014 | -0.06 | -19.63% |
| 2013 | -0.07 | 9.40% |
| 2012 | -0.06 | -37.20% |
| 2011 | -0.10 | 8.66% |
| 2010 | -0.09 | 0.00% |
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -1,099.26% |
US
|
|
| -28.36 | 884.56% |
US
|
|
| -24.57 | 752.93% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -1,153.02% |
NL
|
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.